Compare Hasbro, Inc. (HAS) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Mesoblast Limited — how do they compare? Hasbro, Inc. trades at $87.82 (market cap $11.53B), while Mesoblast Limited trades at $16.36 (market cap $2.17B). The key difference: Hasbro, Inc. is far larger — about 5.3× Mesoblast Limited's market cap, and Hasbro, Inc. pays a 3.44% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| HAS | MESO | |
|---|---|---|
Market Cap | $11.53B | $2.17B |
Sector | Consumer Cyclical | Technology |
52-Week High | $105.88 | $20.96 |
52-Week Low | $70.95 | $12.88 |
Enterprise Value | $13.80B | $2.17B |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $81.56, showing minimal daily movement with a 0.01% gain. The stock exhibits a bearish technical signal, with RSI indicating overbought conditions near-term. Fundamentally, the company reported a net loss of -$322.4M in 2025 despite revenue growth to $4.7B, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights upcoming Q2 2026 earnings and new product launches like Blooms by Play-Doh targeting adult consumers.
The outlook remains mixed with analyst consensus leaning bullish (51.5% buy ratings) and a $104.75 price target suggesting 28% upside. Key risks include persistent negative profit margins, high debt levels, and competitive pressures in the toy industry. Earnings performance on July 21 will be critical for near-term direction.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
